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Aim. The aim of this study is to determine the signiﬁcance of postoperative sequential measurements of serum CA19-9 in patients
with extremely low serum level. Patients and Methods. Serum level of CA19-9 of 1096 patients who underwent surgery was
measured preoperatively and every three months after surgery for 5 years. Patients with CA19-9 level of less than 2U/mL at
the time of diagnosis were deﬁned as Extremely Low CA19-9 (ELCA). Results. One hundred and seven patients (9.8%) were ELCA.
Of these, 86 underwent surgery with curative intent. Serum levels of CA19-9 in patients who did not undergo curative resection
(N = 12) and who developed recurrence (N = 10) were less than 2.0U/mL in all occasions during followup. In all patients
without recurrence, serum level of CA19-9 also remained less than 2.0U/mL. Conclusion. In patients with extremely low CA19-9,
who consist of 9.8% of colorectal carcinoma cases, postoperative sequential measurement of serum level of CA19-9 contributed
neither to assessment of curability of surgical resection nor to detection of recurrence.
Copyright © 2009 Yutaka J. Kawamura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
For patients with colorectal carcinoma, assessment of cur-
ability of the surgery as well as that of recurrence is a very
important issue. In fact, the close follow up program aiming
at early detection of the recurrence after potentially curative
surgery has been reported to improve survival rate [1–6].
Although the “best” program for detection of the recurrence
and for the treatment failure is not yet determined, the
combination of two modalities such as imaging studies and
tumor markers is generally used.
Among tumor markers used in the ﬁeld of gastroen-
terology, carcinoembryonic antigen (CEA) has been recom-
mended in several guidelines and widely used for postop-
erative follow up as well as for the assessment of eﬃcacy
of the treatment [7–9]. CA19-9 has also been used as a
tumor marker for colorectal carcinoma [10–13], usually
accompanied with CEA [14–17].
CA19-9 is an antibody to carbohydrate chain sialyl Lewis
a (sLea) which is synthesized by gylcosyltransferases [18],
and it is well known that in certain group of patients serum
level of CA19-9 is very low [19, 20]. However, little is known
about the serum level of CA19-9 in these patients with
special regards to progression and recurrence of colorectal
carcinoma. The aim of this study is to clarify the changes
of serum level of CA19-9 in these patients and elucidate its
clinical signiﬁcance.
2.MaterialsandMethods
Patients with colorectal carcinoma who were treated from
2000 to 2005 in our department were studied. Serum level of
CA19-9 was measured preoperatively and every three month
for 5 years postoperatively. If postoperative serum CA19-
9 was elevated above the normal limit, the measurement
was done after one month. And if elevation continued,
imaging study was performed. In this study, the recurrence
was diagnosed by the imaging studies, not solely by the
elevation of tumor marker. Serum CA19-9 was measured
by chemiluminescence enzyme immunoassay method. The
upper limit of normal range was 37U/mL, and the lowest
measuring limit was 2U/mL. Patients with CA19-9 level
of less than 2U/mL at the time of diagnosis of colorectal
carcinoma were clinically deﬁned as Extremely Low CA19-9
(ELCA). The change of serum CA19-9 level in these patients2 Gastroenterology Research and Practice
Table 1: Clinical characteristics of clinical CA19-9 negative cases (n
= 75).
Age 64.0 (29–86)
Gender (M/F) 65/42
Location
Cecum 8
Ascending 19
Transverse 5
Descending 2
Sigmoid 31
Rectum 42
TNM stage
I3 1
II 32
III 27
IV 17
was analyzed with special regards to recurrence of colorectal
carcinoma.
This study was approved by the Institutional Review
Board. Informed consent from each patient was exempted
by the Institutional Review Board of Jichi Medical University
due to retrospective nature of this study.
3. Results
From 2000 to 2007, 1096 patients with colorectal carcinoma
weretreated.Ofthesepatients,107(9.8%)wereELCA.There
were 65 males and 42 females with mean age of 64.0 (range,
29–86). Mean follow up period was 3.8 years (range: 1.0
to 5.3 years), and serum CA19-9 was measured 1626 times
for these 107 patients. Numbers of patients with carcinoma
in the cecum, ascending colon, transverse colon, descending
colon, sigmoid colon, and rectum were 8, 19, 5, 2, 31, and 42,
respectively. Numbers of patients with clinical stages I, II, III,
and IV were 31, 32, 27, and 17, respectively (Table 1).
Clinical course of these patients was represented in
Figure 1. Of 17 patients with stage IV disease, ﬁve patients
did not undergo surgery, and seven patients under-
went resection with noncurative intent. These 12 patients
remained to be clinically CA19-9 negative during follow up.
All patients with stages I, II, and III and ﬁve patients with
stage IV disease underwent potentially curative surgery, and
15 patients developed recurrence. Serum levels of CA19-9
were less than 2.0U/mL during follow up in patients both
with and without recurrence.
4. Discussion
Early detection of the recurrence after potentially curative
surgery is an important issue in management of the patients
with colorectal carcinoma [1–6]. Several studies revealed
improved survival by intensive postoperative follow up pro-
gram. Although there are diﬀerences in follow up programs
among the studies, the imaging study and the measurement
of serum tumor marker are included in postoperative follow
up.
Measurement of tumor marker is also used in the
assessment of eﬃcacy of chemotherapy, especially in those
without measureable disease [21, 22].
sLea, which is recognized by CA19-9, is a carbohydrate
chain which is expressed on tumor cells and is known to
play a role in adhesion between tumor cells and endothelial
cells [18]. sLea is secreted into the serum and is used as
a tumor marker for pancreatic, hepatobiliary, gynecolog-
ical, and colorectal carcinoma [9, 23–25]. Several studies
revealed the usefulness of the measurement of serum CA19-
9[ 10–15, 26–29]; however, some studies failed to show its
usefulness [30–34], and measurement of CA19-9 has not
been recommended in guidelines [7–9]. Main focus of the
previous studies was its accuracy in terms of predicting
prognosis and its relevance to recurrence, though, only a few
studies paid attention for patients with low serum CA19-9
value [19, 20].
In this study, we analyzed the serum level of CA19-9 in
patients with colorectal carcinoma in order to clarify the
changing pattern in serum CA19-9 and to determine the
clinical role of its measurement. CA19-9 is an antigen which
recognizes carbohydrate chain sLea, and the value of CA19-
9 means the amount of the carbohydrate chains in sera,
which is called secreted type sLea. The amount of secreted
type sLea is determined by phenotype of both the Lewis (Le)
and secretor (Se) genes. Narimatsu studied the correlation
between phenotype of these two genes and the amount of
serum sLea and found that there is no secretion of sLea in
patientswithphenotypeofle/leandse/se.However,thereare
onlyafewstudiesconcerningpatientswithlowserumCA19-
9 level. In this study, we deﬁned ELCA as having lower than
measuring limit and studied the relation of clinical course
and serum level of CA19-9 [19, 20].
Although the synthesis of CA19-9 increases in a certain
group of patients with colorectal carcinoma, particularly
those with advanced disease, this study demonstrated that
serum level of CA19-9 remains lower than the measurable
limit in all ELCA cases irrespective of the stage at the time
of diagnosis, progression, and recurrence. Our clinical deﬁ-
nition of ELCA may include not only genetic Lewis negative
cases but also the case with very weak expression of CA19-
9; however, with our broad deﬁnition of Lewis negativity,
our study showed no beneﬁt of serial measurement of serum
CA19-9 in patients with colorectal carcinoma whose serum
level of CA19-9 was lower than measurable limit at the initial
assessment.
Further investigation is necessary to elucidate the signiﬁ-
canceofCA19-9inentirepatientswithcolorectalcarcinoma;
however, we found that our criterion of ELCA is practically
useful to determine the group of patients for whom serial
measurement of serum CA19-9 is not contributory for clini-
cal management. Additionally, because the previous studies
focusing on the clinical signiﬁcance of CA19-9 included
patients who do not secrete CA19-9, who consisted of 9.8%
of the patients with colorectal carcinoma, the exclusion
of these patients may provide more precise information
concerning the clinical signiﬁcance of serum CA19-9.Gastroenterology Research and Practice 3
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Figure 1: Schematic representation of clinical course of clinical CA19-9 cases.
We conclude that the measurement of serum CA19-
9 should be omitted irrespective of clinical setting if the
result of the ﬁrst measurement of serum CA19-9 was less
than lower limit. Because CA19-9 was used in variety
of adenocaricnoma, we believe that further investigation
concerning the clinical signiﬁcance of CA19-9 in patients
withotherorganmalignancieswithlessthanmeasuringlimit
may facilitate the saving of medical cost.
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